Telemedicine offers a unique opportunity to expand access to obesity care. The transition to telemedicine and exclusive use of telemedicine for obesity treatment was rapid during the COVID-19 pandemic. The interest in receiving treatment has been further spurred by the introduction of the latest generation of anti-obesity medications that are highly effective. This combination—increased use of telemedicine and increased demand for obesity treatment—has introduced significant changes in the traditional delivery of obesity care within a short timeframe. These new models of care create unique questions regarding standards for provider responsibility, design of care delivery systems, and expectations for what is considered high quality care. The rise of next generation anti-obesity medication underscores this need as these medications have the potential to generate significant weight loss with minimal oversight, yet providers must ensure eligibility and routinely monitor patients’ progress to minimize adverse events. Using a case study and research in over 25,000 patients, the presenter will discuss the implementation of clinical care guidelines in telemedicine for obesity care and the impact on weight-related outcomes it has had on its member base.

CME/CE Expiration Date: 4/26/27

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.